Synthesis and antibacterial activity of adamantyl substituted pyrimidines

Acta Poloniae Pharmaceutica - Drug Research

Volumn 61, Issue 6, 2004, Pages 455-460

  Orzeszko, Barbara ^a   Laudy, Agnieszka Ewa ^b   Starościak, Bohdan Jerzy ^b   Orzeszko, Andrzej ^c,d   Kazimierczuk, Zygmunt ^c,e  

^a WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^d MILITARY UNIVERSITY OF TECHNOLOGY   (Poland)

^e MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Antimicrobial activity; S substituted 6 adamantylated pyrimidines

Indexed keywords

6 ADAMANT 1 YL 2 METHYL 3H PYRIMIDINE 4 THIONE; 6 ADAMANT 1 YL 2 THIOXO 2,3 DIHYDRO 1H PYRIMIDIN 4 ONE; 6 ADAMANTYLPYRIMIDINE; ANTIINFECTIVE AGENT; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ANTIBACTERIAL ACTIVITY; COLONY FORMING UNIT; CONFERENCE PAPER; DRUG STRUCTURE; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; THIN LAYER CHROMATOGRAPHY;

ADAMANTANE; ANTI-BACTERIAL AGENTS; BACTERIA; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES;

EID: 13244270063     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Davies W.L., Grunert R.R., Haff R.F., McGahen J.W., Neumayer E.M., Paulshock M., Watts J.C., Wood J.C., Hermann T.R., Hoffmann E.C.: Science (Washington DC), 144, 282 (1964).
2. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G.: Neurosci. Biobeh. Revs. 21, 455 (1997).
3. Evidente V.G., Adler C.H., Caviness J.N., Gwinn-Hardy K.: Clin. Neuropharm. 22, 30 (1999).
4. Jain K.K.: Expert Opinion Invest. Drugs 9, 1397 (2000).
5. Shibata Y., Shichita M., Sasaki K., Nishimura K., Hashimoto Y., Iwasaki S.: Chem. Pharm. Bull. 43, 177 (1995).
6. Kazimierczuk Z., Górska A., Świtaj T., Lasek W.: Bioorg. Med. Chem. Lett. 11, 1197 (2001).
7. Maurin J.K., Lasek W., Górska A., Świtaj T., Wamil M., Młynarczuk I., Kazimierczuk Z.: Anti-Cancer Drug Design 16, 73 (2001).
8. Orzeszko A., Lasek W., Świtaj T., Stoksik B., Kamińska B.: Farmaco 58, 371 (2003).
9. Górska A., Świtaj T., Młynarczuk I., Lasek W., Kazimierczuk Z.: Acta Polon. Pharm.-Drug Res., 59, 415 (2002).
10. Płachta D., Starościak B.J.: Acta Polon. Pharm. 51, 51 (1994)
11. Papadaki-Valiraki A., Papakonstantinou-Garoufalias S., Makaros P., Chytyroglou-Lada A., Hosoya M., Balzarini J., deClerq E.: Farmaco 48, 1091 (1993).
12. Perrakis A., Antoniadou-Vyza E., Tsitsa P., Lamzin V.S., Wilson K.S., Hamodrakas S.J.: Carbohydr. Res. 317, 19 (1999).
13. Orzeszko A., Lasek W., Świtaj T., Stoksik B., Kamińska B.: Farmaco 58, 371 (2003).
14. Orzeszko B, Kazimierczuk Z, Maurin J.K., Laudy A.E., Starościak B.J., Vilpo, J., Vilpo L., Balzarini J., Orzeszko A.: Farmaco (in press).
15. Kalodera Z., Popejnak S., Blazevic N., Petrak T.: Pharmazie 52, 885(1997).